Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study

BACKGROUND: Bacillus Calmette–Guerin (BCG) maintenance therapy is the standard adjuvant treatment of high- and intermediate-risk non-muscle-invasive bladder cancer (NMIBC). However, the problems of shortages and the adverse effects, both local and systemic, that it causes lead to the search for alte...

Descripción completa

Detalles Bibliográficos
Autores principales: Arrabal Polo, Miguel Ángel, Melgarejo Segura, María Teresa, Yáñez Castillo, Yaiza, Morales Martínez, Ana, Pareja Vílchez, Manuel, Arrabal Martín, Miguel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035471/
https://www.ncbi.nlm.nih.gov/pubmed/36952006
http://dx.doi.org/10.1007/s00432-023-04688-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035471/
https://www.ncbi.nlm.nih.gov/pubmed/36952006
http://dx.doi.org/10.1007/s00432-023-04688-0

Ejemplares similares